Reading COCP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COCP free→Reading COCP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COCP free→QuarterlyIQ Insights · COCP
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Chief Executive Officer — James Sapirstein: James Sapirstein was appointed as the new CEO of Cocrystal Pharma, Inc.
Results of Operations and Financial Condition. On November 14, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal year ended December 31, 2025 and providing certain business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of or otherwise subject to the liabili…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Cocrystal Pharma, Inc. (the “Company”) sadly learned on March 10, 2026 that Dr. Anthony Japour, a member of the Company’s board of directors, passed away. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. C…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On January 9, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of Cocrystal Pharma, Inc. (the “Company”) approved the grant of non-qualified stock options to the Company’s directors, executive officers and a certain consultant. The non-qualified stock options are granted under the Company’s 2025 Equity Incentive Plan…
Results of Operations and Financial Condition On November 14, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2025 and providing certain business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of or otherwise subject to the liab…
The sale of units was exempt from registration based upon Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D promulgated thereunder. Each Purchaser is an accredited investor and acquired the units for investment.
Entry into Material Definitive Agreement. On October 28, 2025, Cocrystal Pharma, Inc., a Delaware corporation (the “Company” or “Cocrystal”) entered into a Securities Purchase Agreement (“SPA”) with four accredited investors (the “Purchasers”) under which the Purchasers purchased a total of 739,426 units of the Company’s securities. The units were priced at-the-market under the rules of the Nasdaq Stock Market at a purchase price of $1.39 per unit. Each unit consisted of one share of common s…
Regulation FD Disclosure. On October 30, 2025, the Company issued a press release announcing the private placement described above in
Entry into a Material Definitive Agreement. Registered Direct Offering On September 12, 2025, Cocrystal Pharma, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with certain accredited investors (each, an “Investor” and collectively the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors (i) in a registered direct offering, an aggregate of 2,764,710 shares (the “Shares”) of the Company’s common stock, par…
Unregistered Sale of Equity Securities. The information set forth in
Regulation FD Disclosure. On September 12, 2025, Cocrystal Pharma, Inc. (“the Company”) issued a press release announcing the pricing of a registered direct offering of common stock and a concurrent private placement of warrants. A copy of the press release is furnished as Exhibit 99.1. The information contained in the press releases attached as Exhibit 99.1, respectively, to this Report shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or other…
Results of Operations and Financial Condition On August 14, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exch…
Results of Operations and Financial Condition On May 15, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchan…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On April 2, 2025, the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) approved and adopted the 2025 Equity Incentive Plan (the “Plan”), which has an effective date of March 31, 2025. The principal features of the Plan are summarized below, which summary is qualified in its entirety by reference to the full text of the…
Results of Operations and Financial Condition On March 31, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exch…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.